News
LUNG
1.550
+0.65%
0.010
Weekly Report: what happened at LUNG last week (0511-0515)?
Weekly Report · 5d ago
Weekly Report: what happened at LUNG last week (0504-0508)?
Weekly Report · 05/11 10:34
Pulmonx publishes investor presentation on Zephyr valves for severe emphysema treatment
PUBT · 05/05 05:52
Weekly Report: what happened at LUNG last week (0427-0501)?
Weekly Report · 05/04 10:30
Pulmonx Earnings Call: Margin Gains Amid Growth Pause
TipRanks · 05/01 00:58
Lake Street Remains a Buy on Pulmonx (LUNG)
TipRanks · 04/30 16:36
Pulmonx (LUNG) Q1 2026 Earnings Transcript
The Motley Fool · 04/30 16:25
Analysts Offer Insights on Healthcare Companies: Align Tech (ALGN), AbCellera Biologics (ABCL) and Pulmonx (LUNG)
TipRanks · 04/30 15:31
Pulmonx Is Maintained at Buy by D. Boral Capital
Dow Jones · 04/30 12:18
Pulmonx Price Target Maintained With a $14.00/Share by D. Boral Capital
Dow Jones · 04/30 12:18
Analysts Conflicted on These Healthcare Names: Teladoc (TDOC), Madrigal Pharmaceuticals (MDGL) and Pulmonx (LUNG)
TipRanks · 04/30 11:20
Pulmonx reiterates $90M-$92M 2026 revenue guidance amid cost cuts and expects return to growth in 2H 2026
Seeking Alpha · 04/30 05:22
*Pulmonx 1Q Rev $20.6M >LUNG
Dow Jones · 04/29 20:29
Pulmonx Q1 revenue falls, slightly beats estimates
Reuters · 04/29 20:22
Pulmonx GAAP EPS of -$0.33, revenue of $20.6M
Seeking Alpha · 04/29 20:22
BRIEF-Pulmonx Q1 EPS USD -0.33
Reuters · 04/29 20:05
*Pulmonx 1Q Loss/Shr 33c >LUNG
Dow Jones · 04/29 20:05
Pulmonx to present at Bank of America Securities Health Care Conference
PUBT · 04/28 20:18
Weekly Report: what happened at LUNG last week (0420-0424)?
Weekly Report · 04/27 10:34
Weekly Report: what happened at LUNG last week (0413-0417)?
Weekly Report · 04/20 10:29
More
Webull provides a variety of real-time LUNG stock news. You can receive the latest news about Pulmonx Corp through multiple platforms. This information may help you make smarter investment decisions.
About LUNG
Pulmonx Corporation is a commercial-stage medical technology company. The Company provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.